Biopharmx Corp (BPMX) Short Interest Update

Biopharmx Corp (NYSEAMERICAN:BPMX) was the recipient of a significant decline in short interest in the month of January. As of January 12th, there was short interest totalling 6,056,385 shares, a decline of 4.2% from the December 29th total of 6,319,421 shares. Based on an average trading volume of 5,768,971 shares, the days-to-cover ratio is currently 1.0 days. Currently, 5.7% of the shares of the company are short sold.

Shares of Biopharmx (BPMX) opened at $0.13 on Thursday. The stock has a market cap of $16.18, a P/E ratio of -0.48 and a beta of 1.33. Biopharmx has a 1 year low of $0.10 and a 1 year high of $0.90.

Biopharmx (NYSEAMERICAN:BPMX) last released its quarterly earnings data on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05).

Separately, Maxim Group reaffirmed a “buy” rating and set a $1.50 price target on shares of Biopharmx in a report on Friday, December 8th.

In other Biopharmx news, Director Stephen Morlock acquired 330,000 shares of the company’s stock in a transaction that occurred on Friday, November 24th. The shares were bought at an average price of $0.15 per share, with a total value of $49,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The disclosure for this sale can be found here.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at

Biopharmx Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.

Leave a Reply